Novel bisphosphonate compound FYB-931 preferentially inhibits aortic calcification in vitamin D3-treated rats

  • Koichi IshidaEmail author
  • Naoki Ashizawa
  • Koji Matsumoto
  • Seiichi Kobashi
  • Naoki Kurita
  • Takashi Shigematsu
  • Takashi Iwanaga
Original Article


In patients with chronic kidney disease (CKD) or those undergoing hemodialysis, pathological calcific deposition known as ectopic calcification occurs in soft tissue, resulting in a life-threatening disorder. A potent and effective inhibitor of ectopic calcification is eagerly expected. In the current study, the effects of FYB-931, a novel bisphosphonate compound synthesized for the prevention of ectopic calcification, were compared with those of etidronate using both in vitro and in vivo models. In vitro, FYB-931 inhibited calcification of human aortic smooth muscle cells induced by high phosphate medium in a concentration-dependent manner, and the effect was slightly more potent than that of etidronate. In vivo, rats were administered with three subcutaneous injections of vitamin D3 to induce vascular calcification, and were given FYB-931 (1.5, 5, or 10 mg/kg) or etidronate (9, 30, or 60 mg/kg) orally once daily for 14 days. The increased aortic phosphorus content as an index of vascular calcification was inhibited by both FYB-931 and etidronate in a dose-dependent manner; however, FYB-931 was 10 times more potent than etidronate. FYB-931 inhibited serum tartrate-resistant acid phosphatase (TRACP) activity as a bone resorption marker 5.2 times more potently than etidronate. FYB-931, but not etidronate, significantly decreased serum phosphorus levels. The preferential inhibition of aortic calcification by FYB-931 suggested that possible additional effect including a decline in serum phosphorus may lead to an advantage in terms of its efficacy.


Bisphosphonate Rat Calcification Bone resorption marker Serum phosphorus 


Compliance with ethical standards

Conflict of interest

Dr. Takashi Shigematsu serves as a consultant for Fuji Yakuhin. The manuscript does not contain clinical studies or patient data.


  1. 1.
    Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA (2014) Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int 85:142–150CrossRefGoogle Scholar
  2. 2.
    Giachelli CM (2004) Vascular calcification mechanisms. J Am Soc Nephrol 15:2959–2964CrossRefGoogle Scholar
  3. 3.
    Giachelli CM (1999) Ectopic calcification: gathering hard facts about soft tissue mineralization. Am J Pathol 154:671–675CrossRefGoogle Scholar
  4. 4.
    Matsuoka M, Iseki K, Tamashiro M, Fujimoto N, Higa N, Touma T, Takishita S (2004) Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 8:54–58CrossRefGoogle Scholar
  5. 5.
    Yiu AJ, Callaghan D, Sultana R, Bandyopadhyay BC (2015) Vascular calcification and stone disease: a new look towards the mechanism. J Cardiovasc Dev Dis 2:141–164CrossRefGoogle Scholar
  6. 6.
    Karwowski W, Naumnik B, Szczepański M, Myśliwiec M (2012) The mechanism of vascular calcification: a systematic review. Med Sci Monit 18:1–11CrossRefGoogle Scholar
  7. 7.
    Wu M, Rementer C, Giachelli CM (2013) Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int 93:365–373CrossRefGoogle Scholar
  8. 8.
    Hashiba H, Aizawa S, Tamura K, Shigemastu T, Kogo H (2004) Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. Ther Apher Dial 8:241–247CrossRefGoogle Scholar
  9. 9.
    Hashiba H, Aizawa S, Tamura K, Kogo H (2006) Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. Ther Apher Dial 10:59–64CrossRefGoogle Scholar
  10. 10.
    Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H (2004) Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44:680–688CrossRefGoogle Scholar
  11. 11.
    Koshiyama H, Nakamura Y, Tanaka S, Minamikawa J (2000) Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes. J Clin Endocrinol Metab 85:2793–2796Google Scholar
  12. 12.
    Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268CrossRefGoogle Scholar
  13. 13.
    Price PA, Faus SA, Williamson MK (2001) Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21:817–824CrossRefGoogle Scholar
  14. 14.
    Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG (2010) Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 56:57–68CrossRefGoogle Scholar
  15. 15.
    Tankó LB, Qin G, Alexandersen P, Bagger YZ, Christiansen C (2005) Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int 16:184–190CrossRefGoogle Scholar
  16. 16.
    Zavaczki E, Jeney V, Agarwal A, Zarjou A, Oros M, Katkó M, Varga Z, Balla G, Balla J (2011) Hydrogen sulfide inhibits the calcification and osteoblastic differentiation of vascular smooth muscle cells. Kidney Int 80:731–739CrossRefGoogle Scholar
  17. 17.
    Ferrer MD, Pérez MM, Cànaves MM, Buades JM, Salcedo C, Perelló J (2017) A novel pharmacodynamic assay to evaluate the effects of crystallization inhibitors on calcium phosphate crystallization in human plasma. Sci Rep 7:6858CrossRefGoogle Scholar
  18. 18.
    Ziegler SG, Ferreira CR, MacFarlane EG, Riddle RC, Tomlinson RE, Chew EY, Martin L, Ma CT, Sergienko E, Pinkerton AB, Millán JL, Gahl WA, Dietz HC (2017) Ectopic calcification in pseudoxanthoma elasticum responds to inhibition of tissue-nonspecific alkaline phosphatase. Sci Transl Med 9:1–25CrossRefGoogle Scholar
  19. 19.
    Marma MS, Xia Z, Stewart C, Coxon F, Dunford JE, Baron R, Kashemirov BA, Ebetino FH, Triffitt JT, Russell RG, McKenna CE (2007) Synthesis and biological evaluation of α-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate. J Med Chem 50:5967–5975CrossRefGoogle Scholar
  20. 20.
    Takahashi N, Udagawa N, Suda T (2014) Vitamin D endocrine system and osteoclasts. Bonekey Rep 3:1–9CrossRefGoogle Scholar
  21. 21.
    Fleisch HA, Russell RGG, Bisaz S, Mühlbauer RC, Williams DA (1970) The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1:12–18CrossRefGoogle Scholar
  22. 22.
    Grases F, Sanchis P, Perelló J, Isern B, Prieto RM, Fernández-Palomeque C, Torres JJ (2007) Effect of crystallization inhibitors on vascular calcifications induced by vitamin D: A pilot study in Sprague-Dawley rats. Circ J 71:1152–1156CrossRefGoogle Scholar
  23. 23.
    Duan X, Zhou Y, Teng X, Tang C, Qi Y (2009) Endoplasmic reticulum stress-mediated apoptosis is activated in vascular calcification. Biochem Biophys Res Commun 387:694–699CrossRefGoogle Scholar
  24. 24.
    Price PA, Buckley JR, Williamson MK (2001) The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr 131:2910–2915CrossRefGoogle Scholar
  25. 25.
    Saji F, Shigematsu T, Sakaguchi T, Ohya M, Orita H, Maeda Y, Ooura M, Mima T, Negi S (2010) Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH. Am J Physiol Renal Physiol 299:F1212–F1217CrossRefGoogle Scholar
  26. 26.
    Boskey A (2003) Bone mineral crystal size. Osteoporos Int 14:S16–S21CrossRefGoogle Scholar
  27. 27.
    Neven EG, De Broe ME, D’Haese PC (2009) Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? Kidney Int 75:580–582CrossRefGoogle Scholar
  28. 28.
    Zhou S, Fang X, Xin H, Guan S (2013) Effects of alendronate on the Notch1-RBP-Jk signaling pathway in the osteogenic differentiation and mineralization of vascular smooth muscle cells. Mol Med Rep 8:89–94CrossRefGoogle Scholar
  29. 29.
    Hu ML, Huang Y, Zheng ZH, Lei Y, Liu RJ, Wang XH, Lindholm B, Yu XQ (2012) Zoledronate inhibits phosphate and bone morphogenic protein 2-induced extracellular calcification of vascular smooth muscle cells in vitro. Exp Ther Med 3:841–844CrossRefGoogle Scholar
  30. 30.
    Masuzaki T, Ayukawa Y, Moriyama Y, Jinno Y, Atsuta I, Ogino Y, Koyano K (2010) The effect of a single remote injection of statin-impregnated poly (lactic-co-glycolic acid) microspheres on osteogenesis around titanium implants in rat tibia. Biomaterials 31:3327–3334CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  • Koichi Ishida
    • 1
    Email author
  • Naoki Ashizawa
    • 1
  • Koji Matsumoto
    • 1
  • Seiichi Kobashi
    • 1
  • Naoki Kurita
    • 1
  • Takashi Shigematsu
    • 2
  • Takashi Iwanaga
    • 1
  1. 1.Research Laboratories 2Fuji Yakuhin Co., Ltd.SaitamaJapan
  2. 2.Department of NephrologyWakayama Medical UniversityWakayamaJapan

Personalised recommendations